NCT02433119

The Efficacy and Safety of OROSARTAN® Versus CODIOVAN® in Patients With Essential Hypertension Uncontrolled With Monotherapy

A Multi-center, Randomized, Double-blind, Phase IV Clinical Trial to Compare the Efficacy and Safety of OROSARTAN® Tablet 5/160mg Versus CODIOVAN® Tablet 160/12.5mg in Patients With Essential Hypertension Uncontrolled With Valsartan 160mg Monotherapy

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 238 (actual)
• Sponsor: Dong-A ST Co., Ltd. · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

A multi-center, randomized, double-blind, phase IV clinical trial to compare the efficacy and safety of OROSARTAN® tablet 5/160mg versus CODIOVAN® tablet 160/12.5mg in patients with essential hypertension uncontrolled with valsartan 160mg monotherapy

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	OROSARTAN® 5/160mg
DRUG	CODIOVAN® 160/12.5mg

Timeline

• Start date: 2015-03-16
• Primary completion: 2016-09-08
• Completion: 2016-09-08
• First posted: 2015-05-04
• Last updated: 2017-04-12

Locations

1 site across 1 country: South Korea